Boehringer Ingelheim and Cognizant announce the launch of a unified cloud platform to bring innovative therapies to patients faster
Rhea-AI Summary
Cognizant (CTSH) and Boehringer Ingelheim have announced the successful launch of Phase One of their 'One Medicine Platform,' a unified cloud platform powered by Veeva Development Cloud. The new system replaces over 20 legacy platforms, streamlining medicinal development processes and enhancing operational efficiencies.
The platform, implemented by Cognizant as the prime system integrator in collaboration with Syneos Health Consulting and Veeva, unifies clinical data, operations, regulatory, and quality functions. The system is designed to serve 15,000+ users working in Clinical Development programs, addressing previous challenges of disconnected vendor systems and complex workflows.
Phase Two of the project will focus on enhancing Boehringer's clinical operations and integrating additional regulatory function modules. The implementation aims to resolve data challenges, reduce latencies, and accelerate the company's product go-to-market timeline.
Positive
- Major contract implementation success with Boehringer Ingelheim, demonstrating Cognizant's capability in large-scale digital transformation
- Platform serves 15,000+ users, indicating significant contract value and recurring revenue potential
- Phase Two expansion confirms project success and potential for additional revenue
Negative
- None.
Insights
Cognizant has successfully delivered Phase One of a strategic digital transformation initiative for Boehringer Ingelheim, implementing an integrated cloud platform that consolidates over 20 legacy systems into a unified ecosystem. This marks a significant milestone in their partnership announced in 2023.
The "One Medicine Platform," powered by Veeva Development Cloud, streamlines pharmaceutical development processes across clinical, regulatory, and quality functions - directly impacting workflows for more than 15,000 users. As prime system integrator, Cognizant provided comprehensive services spanning program management, architecture design, integration, and validation.
Technology Integration Expert: The complexity of this implementation demonstrates Cognizant's advanced capabilities in life sciences technology integration. By replacing disparate systems with a unified platform, Cognizant addresses a critical industry challenge: fragmented data environments that slow drug development. The successful execution strengthens Cognizant's competitive position in the life sciences vertical, where digital transformation demands continue to accelerate. The multi-phase nature of this project suggests ongoing revenue potential as the relationship expands into Phase Two. While financial terms weren't disclosed, the project's scale indicates material value, with Cognizant demonstrating expertise in both technical implementation and organizational change management across multiple functions and user groups.
Life Sciences Consultant: This implementation addresses pharmaceutical R&D's most persistent challenge - siloed operations across development functions. By unifying clinical data, operations, regulatory affairs, and quality systems, Boehringer can significantly compress development timelines, potentially accelerating time-to-market for new therapies. The replacement of 20+ legacy systems also suggests substantial technical debt reduction and operational cost savings. For Cognizant, this project showcases their specialized knowledge in pharmaceutical development processes and validation requirements - a high-barrier entry point for technology providers. The client testimonial emphasizing operational efficiencies indicates measurable business impact, strengthening Cognizant's credentials for similar transformations across the pharmaceutical sector.
Powered by the Veeva Development Cloud, the system brings together previously disparate functions to streamline the medicinal development process and enhance operational efficiencies
Boehringer's "One Medicine Platform," replaces over 20 legacy platforms. The initiative unifies medicinal development processes and data sources into a connected ecosystem, with the aim of enhancing cross-functionality and operational efficiencies.
Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the project entails services such as program management, system architecture and design, training, integration, migration, testing and validation. Cognizant partnered closely with Syneos Health Consulting for business process engineering and with Veeva for configuration and system architecture and design.
In Phase One, Cognizant successfully supported implementation across clinical data, clinical operations, regulatory, and quality functions, enabling Boehringer Ingelheim's move onto the unified platform. This holistic approach is expected to streamline the workflows of 15,000+ users working in Clinical Development programs. In Phase Two, the collaborators look to further enhance Boehringer's clinical operations practice and integrate additional modules into its regulatory function.
"For years, Boehringer Ingelheim used multiple vendor systems which lacked the ability to communicate with each other, which led to complex workflows. The launch of our One Medicine Platform revolutionizes our medicinal development processes and takes our operational efficiencies to the next level," said Oliver Fink, Head Learning, Processes & Digitalization, Global Quality Medicine at Boehringer Ingelheim.
"We are pleased to achieve this program milestone in our collaboration with Boehringer Ingelheim," said Gagan Syal, Head of Life Sciences, EMEA & APAC, at Cognizant. "With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams, we have been able to execute this project in record-time."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes, and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
About Boehringer Ingelheim
https://www.boehringer-ingelheim.com/ Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.
For more information, contact: GlobalPR@cognizant.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster-302397176.html
SOURCE Cognizant Technology Solutions
FAQ
What is the scope of Cognizant's (CTSH) One Medicine Platform implementation for Boehringer Ingelheim?
How many users will benefit from the new Cognizant (CTSH) platform at Boehringer Ingelheim?
What are the key partners involved in Cognizant's (CTSH) platform implementation?
What improvements does the Cognizant (CTSH) One Medicine Platform bring to Boehringer Ingelheim?
